TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replication

TRIM7 通过泛素化 SARS-CoV-2 膜蛋白来限制细胞凋亡和病毒复制。

阅读:2
作者:Maria Gonzalez-Orozco ,Hsiang-Chi Tseng ,Adam Hage ,Hongjie Xia ,Padmanava Behera ,Kazi Afreen ,Yoatzin Peñaflor-Tellez ,Maria I Giraldo ,Matthew Huante ,Lucinda Puebla-Clark ,Sarah van Tol ,Abby Odle ,Matthew Crown ,Natalia Teruel ,Thomas R Shelite ,Joaquin Moreno-Contreras ,Kaori Terasaki ,Shinji Makino ,Vineet Menachery ,Mark Endsley ,Janice J Endsley ,Rafael J Najmanovich ,Matthew Bashton ,Robin Stephens ,Pei-Yong Shi ,Xuping Xie ,Alexander N Freiberg ,Ricardo Rajsbaum

Abstract

SARS-CoV-2 is a highly transmissible virus that causes COVID-19 disease. Mechanisms of viral pathogenesis include excessive inflammation and viral-induced cell death, resulting in tissue damage. Here we show that the host E3-ubiquitin ligase TRIM7 acts as an inhibitor of apoptosis and SARS-CoV-2 replication via ubiquitination of the viral membrane (M) protein. Trim7-/- mice exhibit increased pathology and virus titers associated with epithelial apoptosis and dysregulated immune responses. Mechanistically, TRIM7 ubiquitinates M on K14, which protects cells from cell death. Longitudinal SARS-CoV-2 sequence analysis from infected patients reveal that mutations on M-K14 appeared in circulating variants during the pandemic. The relevance of these mutations was tested in a mouse model. A recombinant M-K14/K15R virus shows reduced viral replication, consistent with the role of K15 in virus assembly, and increased levels of apoptosis associated with the loss of ubiquitination on K14. TRIM7 antiviral activity requires caspase-6 inhibition, linking apoptosis with viral replication and pathology.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。